OVIT (OncoVista Innovative Therapies) Change In Working Capital: $2.39 Mil (TTM As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoVista Innovative Therapies Change In Working Capital?

OncoVista Innovative Therapies OVIT Change In Working Capital is $2.39 Mil as of Sep. 2015.

OncoVista Innovative Therapies's change in working capital for the quarter that ended in Sep. 2015 was $-0.47 Mil.

OncoVista Innovative Therapies's change in working capital for the fiscal year that ended in Dec. 2014 was $2.32 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

OncoVista Innovative Therapies Change In Working Capital Related Terms

OncoVista Innovative Therapies Change In Working Capital Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Change In Working Capital Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Change In Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.42 0.35 0.27 1.05 2.32

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 1.67 0.21 0.99 -0.47

OncoVista Innovative Therapies Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.39 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Working Capital of $2.39 Mil mean?
OncoVista Innovative Therapies (OVIT) has a Change In Working Capital of $2.39 Mil as of Sep. 2015. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for OncoVista Innovative Therapies.
Is OncoVista Innovative Therapies' Change In Working Capital too high?
OncoVista Innovative Therapies' current Change In Working Capital is $2.39 Mil.
How does OncoVista Innovative Therapies' Change In Working Capital compare to RSPI and HSTC?
OncoVista Innovative Therapies' Change In Working Capital of $2.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Biotechnology company?
A good Change In Working Capital depends on the Biotechnology industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for OncoVista Innovative Therapies. OncoVista Innovative Therapies's current Change In Working Capital is $2.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Change In Working Capital of $2.39 Mil. The current Change In Working Capital is $2.39 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Change In Working Capital is $2.39 Mil as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.